SYNH - Earnings call transcript Q3 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen, and welcome to the Syneos Health Third Quarter 2018 Earnings Conference Call. [Operator Instructions] I would like to hand the conference over to Ronnie Speight, Senior Vice President of Investor Relations. Please go ahead, sir.

Ronnie Speight

Good morning, everyone. With me on the call today are Alistair MacDonald, our Chief Executive Officer; Jason Meggs, our Chief Financial Officer; and Michelle Keefe, our President of Commercial Solutions.

press is slide at available the our corresponding www.investor.syneoshealth.com. to remarks prepared on addition release, presentation a to In our website for XXXX, harbor provisions Remarks plans the update Private statements about them. make Reform under disclaim purposes the Act any Litigation prospects to of for safe that forward-looking we company the future of Securities constitute and we and expectations, obligation the forward-looking impact differ materially the important from statements these as may by various standard. a results the Actual factors, to indicated including of changes accounting revenue of result those recognition section are our ended factors discussed our These in XXXX, the XX, XX-K year other risk factors the filings. of for SEC and Form December

we cooperations. as supplement During should discuss which for non-GAAP this considered the measures, These be we in outside in not and financial certain measures will with of our to prepared non-GAAP consider accordance be and measures core effects replacement a call, transactions to exclude of events GAAP.

non-GAAP the turn the of to a would to our like financial Appendix For MacDonald. Alistair? now Alistair measures presentation. the comparable of most GAAP call please to with reconciliation I refer measures, directly over

Alistair MacDonald

call. thank Thank our quarter joining everyone, you, and you third Ronnie. morning, Good for

to a business expectations we commercial build believe model, which quarter, combined engagement we well clinical experiencing, offering. of are awareness our on breadth the customer our resonate we and profitability. As in we to generate and the report the continue our Based momentum our with solid for I’m to marketplace unique continues offerings understanding third pleased exceeded as level of of

quarter. like begin you recognized several of our quarter. the of ahead customer industry third Additionally, phases awards through from operations, all delivery to during our superior integration progress continue highlights the taking to in efforts and by some with our was schedule I’d

driven was solid year-to-date. book-to-bill and quarter an solid strong Integrated Solutions sales across performance Commercial by times of we were that million of net First, contract awards ratio This the awards teams. and by total fueled performance overall X.XXtimes broad-based, $XXX collaboration with overall Clinical, X.XX have and our for

segment revenue our sequentially of with growth Solutions second quarter. XXXX X% Commercial to Second, third returned compared year-over-year quarter and consecutive up for the to the up

acquisition our consulting and safety acquisition and trial post-approval of business, operations a we regulatory, and multiple of Kinapse. deepens arena. the This including closed other clinical expands our in our Third, our pharmacovigilance scope of transparency, facets scale operational Europe. medical and writing and operations, in consulting operations, and quality doubles access delivery consulting and footprint our in clinical Asia-Pacific also and areas capabilities affairs, compliance. of quality and market the capabilities Kinapse our R&D expands It medical

to our offering results a strengthening the Commercial progress Turning Solutions pleased macro our as remain by We to build momentum of continues the team in with environment. business.

were of million In consistent up our the net during sequentially, experienced year-to-date growth in times, addition target to ratio awards X.XX book-to-bill the of $XXX.X a quarter, is of with largely times. level X.XX XX% resulting we which

increase to expectations, XXXX desire the Our pipeline outsourcing drug feedback line levels overall of in exceeding time. new is already approvals over customer a commercial indicating with with near and Commercial FDA growing record growing

key world. one in network Our communications largest the differentiators of business serves represents Commercial health-care-only the as and segment the our full-service Solutions for

customers industry awards. communications their creative multiple with to teams and our outstanding ability commercialization help quarter, the continued goals During recognized demonstrate to their were achieve

experts and digital and campaign the for nonconsumers. deliver. continue digitally Modern Agency For magazine from the excellence medical, the a best best the initiative of received print is Age Digital example, by at GSW also our for advertising customers, commercial focus for Modern Healthcare GSW, largest named marketing Healthcare Impact professional media and Year our our Ad awards native and to Awards. agency, was

continues Solutions Our the in also to market. momentum segment build Clinical

times X.XX resulting particularly strong million, $XXX ratio were small all months. of quarter and and both These segments for awards midsized among Third quarter were core across broad trailing awards customer were net a based the our in XX the book-to-bill to net customers.

also other customers. pharma discussions remain engaged strategic regarding large We relationships in with ongoing

year-to-date with net Given XX% this since XXXX. by XXX, With is our grown of quarter awards, phases approximately expect start-up by under of new backlog growth and third the total been that programs, complexity other driven in revenue this regard It has XXXX. delays. to service the noting X.X% regulatory from of certain growth we large extended has strong up programs year, worth rate on negatively ASC along our X% customer clinical growth impacted

guidance customers’ the in only our proud our site adjusted relationships catalyst align with factors year. in appropriate by on category our our relationships. CRO from to for synergy communications These Award approaches central variety highlight of multichannel these philosophy. focus very expectations focus to operating to want continued fueled be expertise I’m business adjustments and through And Research cost say While revenue strategic of the recently site a Sites Clinical second that our impacting we sites. and Eagle patient to the consecutive of studies EBITDA. to segment, management continued the efforts We the timing the our I to the on Society Clinical and In recruitment to our won minor for our site year, this also data-enabled programs results investigative are capture both use for

XX both is award done this by more than XX,XXX Importantly, countries. sites in

I’d market. commercial like segment, and our strategic platforms to we This investments some technology critical our services seasoned channels for includes multiple success dynamic multichannel updates ongoing talent expanding provide investments. enable Commercial integrated teams ongoing Next, data evolving across and investing customers’ analytics to further Solutions offerings. flexible, our multifunctional in of a our In by rapidly enabled specialized making is marketing strategic Providing to support execution. are on with in

and support channels, we of commercialization needs. a and predictive is on the end-to-end media we example, modifications building timing only inform newly We’ve investments. This example to to continued recently customers’ solutions, or also integrated one in our decisions customer of is engagement are modeling, budget invest For to our team. dynamic ISG, capabilities which being our initiated strategic market developed incorporated new used iterative media

During the adding the with across by third to our development asset performance experienced we customers strengthened work life strategists this product to cycle. team optimize quarter,

create evidence expertise, Phase a also We’re and Process, This a included X commercial data our strategy customer large insights for which clinical cross-functional results award of enables quarter. real-world Trusted operational during the midsized unique across biopharma of to creating a adherence the study strategy utilizing example delivery assets in bolstering an robust and is customer. third and unique a management capabilities, recent team driving both customer approach utilization ISG’s This to Clinical solutions. A Commercial. collaborative

nimble and also technology best-of-breed in of allowing and the to trial We call enhance our agnostic, believe to which to biopharma launch this strategy source manner. investigative capital-efficient digitization We third protocol extrapolation us optimize more options strategy regarding a our each remain and to the continued ahead nuances a curve. strategy product in customer, address to modern similar partnering fluid We flexible to multiple assembly, sites. of parties, our quickly the advances best and leveraging enables dynamic and while data approach with us data how solutions, model, data digital fuel

we recently reduced a and of optimization Our to tools, Award platforms records investigative Medidata program. ability tool burden data-entry and create through Architects recognized delivers sites. integration costs, complex pioneering we and medical studies lines capture as First is to quality. Medidata improved our for data burden an to electronic site part to This Protocol approach seen between customer synthesize accelerated Accelerator oncology where recognized in data are the partnering modeling. when value time and This have systems electronic predictive study and the partners of reduce we work data intelligence technologies the with won meaningful using with Hope was like-minded This

our Finally, team integration on is our also exceeding activities. expectations

by our million. to to XXXX’s We million savings previous reinvestments. We $XX of during total to quarter, realized are, year-to-date third synergies therefore, million bringing $XX prior $XX our estimate our million of $XX increasing strategic $XX million to approximately the realized

continue remain XXXX, realize work and gratitude we Health very colleagues In sincere annually toward my ability Syneos We express in also by in XX,XXX confident let identifying million opportunities. me to $XXX to closing, our additional to worldwide. synergies my

this new both to add from participated this special the Overall, quarter. And a thanks teams teams wanted on industry them and and to our truly members all our team apart. I You that existing of dedication Kinapse. deliver engagement, our make including to focus possible, awards to in customers progress sets our multiple continuing new

our to over for Jason on comments performance. more Now Jason? turn financial let this me

Jason Meggs

Thank everyone. morning, you, and Alistair, good

be on facilitate discussing are the the Slide we Let comparisons. as with current beginning or previous results closed period results period presented, periods, will prior period-to-period standard remind an X. the to as the earliest of the you Consistent on our revenue non-GAAP defined at merger basis me if adjusted under the that

to capital allows realization ASC to pipeline in strategy with and reinvestments include: and service year-over-year expenses. quarter strong the opportunities; with XX% A us drive sequential our under discussing particularly pleased comparisons closing and Solutions the to the For under performance that lower our by accounts facility strong for growth funding accelerated XXX our our costs leverage these synergies full reduction. balance adjusted interest brief to few establishing segment, like our adjusted progress the to business revenue, the third be along ASC excluding continued we exceeding growth; with drive XXXX XXX, acquisition, I deployment EBITDA I of of for and our on items Commercial new future forecast our with growth, reimbursable Kinapse in continued securitization receivable our momentum year; the with return order of of growth of results. the our summary start a to am would will

by under review XXX. Slide ASC show I but XXX, X, results our under we detail. more results Now will I’ll results On discussing our XXX begin both in and financial ASC

for the our timing exchange in last This a million. was segment was the million, grew $XXX.X total third to of awards strong a This driven the trends fluctuated of quarter each for million customer The the in million XXXX was X% modifications. year-over-year headwind increase revenue normalized the improvement $X.X XXXX to quarter the compared of XXXX. for have in due million in which $XXX.X would driven the note X third up months, in by X.X% in during along of was third ASC unfavorable Our for would XXX, of by revenue although also Clinical delays of mix net with new in and studies it and partially awards Clinical X% service growth I current of the net the quarterly the XXXX. revenue under existing is growth $XXX.X first quarter this to segment, Clinical contract range third quarter. revenue quarter from during timing, our been of XX XXXX. of foreign rates that the XXXX backlog, to have If X% $XXX.X of by adjusted an start quarters offset our

posted Clinical revenue only $X from Commercial XX%, the and the unfavorable in along not million $X.X million. benefit $XXX.X from increasing to segment quarter. with revenue returned another realized XXXX in quarter Clinical exchange in million originally included mix Adjusted of in approximately million partially that included increased Commercial XXXX, in This the in a savings for XX.X% margin synergies, and million EBITDA with fourth specifically, XXXX $XXX.X $XXX.X cost benefits the quarter associated quarter growth other of growth of were X% third Our benefit the More third to by our we compared quarter. in to Adjusted year-over-year EBITDA foreign third XX.X%. third for to quarter growth, but sequential of offset an segment. by revenue by Commercial $XXX.X to The expected the million XXXX. also increased

quarter XX.X% primarily half to our the of growth For XXXX to $X.XX of driven the EPS realization impact quarter the Adjusted Adjusted in by of $X.XX EBITDA third were reinvestments of about increased the our reduction growth. XXXX. our third of lower million drive from interest of the diluted increases XX% expense, share million a third $XX.X rate includes during adjusted before million in of to of adjusted synergies XX% strategic of first XXXX, for net the XXXX in EBITDA, the for quarter to third grew of income XXXX. the the the and from in repurchases non-GAAP These quarter tax $XX third XXXX. impact quarter by $XX.X

XX.X% adjusted for total This Now expenses, I of want to adjusted in summarize was the for Adjusted in our which ASC for new income representing $XXX.X growth sequential quarter, $X.XX. EBITDA margin. was growth. of adjusted for the includes comprised million adjusted revenue under the Clinical quarter million a $XXX.X year-to-date. was of XXX, standard. million an billion, adjusted Total the ASC third and results EBITDA million was representing adjusted third Commercial. million, Under total net revenue Total quarter, and is EBITDA XX.X% sequential $XX.X third $X.XX EPS $XXX.X X.X% reimbursable resulting XXX $XXX.X

Now sheet. moving and balance to flow cash

During the million quarter an of from XXXX, flow on third operations cash basis. reported $XXX.X was our as

and DSO cash debt opportunities we X of as days provides capital on ended tuck-in drive balanced ASC combined and acquisitions capital a deployment debt was conditions. management repayment, as the value. million by flow our And deployment repurchases XX cash available $X.XX for on remain approach quarter net with total of to focused as unrestricted Slide share Our activities. well This billion. the We and under market to includes update shareholder determined an debt and quarter XXX. outstanding $XXX.X

During the milestones. quarter, achieved several key we third

First, of XXX from we proceeds Loan reduce outstanding points. the accounts receivable B, basis interest facility in our $XXX.X related utilized million to Term funding cost reducing by our the securitization

with loans, of our million during end to Xx an track of total our to term to $XXX.X since approximately quarter, plan closing net additional the our XXX Second, debt bringing ASC merger we leverage reductions the million, third reduce the our repaid overall of XXXX. by $XX.X on our

is acquisition Kinapse, Third, of we accretive closed to earnings. our which immediately

help disciplines consulting our key highlighted, capabilities in our Alistair operational and this As markets. should in expands transaction growth and multiple fuel

the we non-GAAP expect our the $XX the XX% be taxes tax for cash rate expect XX%. approximately may year rate approximately changes allocation continue income, to of our total fluctuate full tax but The to outlay for due cash continue to to jurisdiction be effective XXXX We the to million to for in taxable year. these

and account taken pipeline, currency estimated factors, our our net rates trends now outlined into guidance expected of based We’ve merger rate. synergies our on guidance, existing rates, foreign on to delays current number as a in our our Turning tax Slide of including X. expected cancellations sales interest current backlog, Further, reimbursements. and and is exchange

upon subsequent any estimated to is repurchases count, diluted third guidance Our based also share share the excluding our quarter.

we EBITDA $XXX to EBITDA as slightly. our are adjusted to management of May we initial and year-to-date in improvements lower during billion start-up our our of result expectations. ASC We delays Therefore, exchange guidance, $X.XX expect to $X to due with year relationships million as given now adjusting third in Despite synergies, guidance in $X.XX of million million complexity and the a as somewhat our guidance reflect cost quarter; $XXX our foreign are new this efficiency following: We XXX Clinical range revenue since well $XX expect our backlog conversion adjusted only a of ongoing the now occurring operational of revenue increased ramp accelerated headwinds billion. the and approximately incremental slower our the and initial protocol extended delays; other study strategic awards to guidance range million. performance, lowering midpoint in in full compared

increasing diluted million fully under our a before EPS Since of business based related diluted our are expected longer approximately which XXX. our strategic We no expected million count under ASC by approximately vary for weighted impact updated million for investments full guidance we and are of among shares, the adjusted ASC year to share XXXX to formal of we $X.XX are our we guidance other things, quarter. of on, Lastly, XXX, XXX.X updating primarily focusing average EPS million, synergies our $XX merger expectations to adjusted interest expense $XXX $XX of the $X.XX. will

you quarter. the to mid-single-digit directional wanted fourth segment. some Commercial Under XXX, for our with revenue sequential in ASC commentary revenue growth in I growth sequential expect mid-double-digit provide Clinical we and our However, segment

We the in EBITDA growth expect mid-double-digit adjusted sequential range.

we we are on based we revenue want guidance, full not ASC today. commentary growth providing directional XXXX XXX on what While provide did to see

growth our expect fee assuming growth. expenses XXXX, in grow reimbursed line revenue direct further accelerate rate in We with to revenue

earlier delays Clinical XX highlighted rates. more estimated current exchange well modest I headwind on segment, to incremental FX we as million start-up the acceleration For our due based as primarily of expect a an

the we our growth more the exceed remarks, be commercial with rapid Operator? Commercial to happy acceleration This For prepared our segment, a rate. opportunity will of any questions. completes our expect market we view to and answer

Operator

[Operator Instructions] And Jones our Goldman first question of comes from Sachs. Robert

Your line is open. now

Robert Jones

the vacuum, Clinical think, I obviously obviously at healthy on bit. like healthy us of guess, looking characterize bookings would kind does Alistair most I declined And side. in pretty and on the a the of Jason, side, Clinical right now I But healthy. look bookings year-over-year, environment a it think just X.XX, as the

was bit a least deeper what how into partnership you we’ve you drove could wondering the bookings little seeing. at I to of other maybe mentioned relative played I delve much been know part strategic underlying that if maybe So slower just than growth you some Curious what that have. of a business a little the wins.

Alistair MacDonald

X.XX think X.X I the months, overall. last think trailing XX we’re I XXXX, about in

So in I book a Obviously, XXXX, backlog awards months. to within stuff the pulls year used think running come that’s changed to so little place of have the honest, a the naturally all pulls that policy through a take award. We that always to to first we And can some of so policy in down that’s the down where little we six bit full little bit. kind be be. next going And way was awards it FSPs. to just only service into that it it booking compared bit hot, our degree, X.X we

as buoyant good the the into time. saying kind of is number think, of lot of in revenue, very funding MSAs in pharma. we I we those strong by become the on That fully And takes type people the of growth SMID. we’ve market. now as that. that’s an big strength what a strong. is we’re environment underneath a And and And the costs bit are believe the seeing kid CRO think Interesting, little negotiations, transitioned a I is and generate two block in new place discussions organization,

XXXX to penetrate So I well done sector, although seeing we in we’ve expect us where sector, start expected in that think, to be. about we that

I a little bit think XXXX. we as that we accelerate go into can

Robert Jones

I acquisition. guess on just follow-up quick one Kinapse the

had guys a immaterial maybe you I sounds think year. bit this little it’s kind year, of it being to like originally, mentioned this helping neutral

just update what accretion in think expectations what as an we or with can fiscal guess, And modest we I how drove So anything part like for ‘XX? of the enterprise on out as that about us modest you look seems then accretion share ‘XX. asset about should to

Alistair MacDonald

Yes, we’ve organization couple Bob. absolutely. with of years, a for is an Kinapse Yes. worked actually

in pull six saw together Kinapse And gaps. one we we platforms the what deal. So single the not in gaps have scale some end-to-end more we and closed capability is actually of us when for and model, gaps gaps deploy those to these merger we started -- about

So that of to it from potential we’ve revenue areas. it’s strong couple platform And kind it quarterly that we nice to putting we’re a the group. positive we’ve that the think, that synergies worked and of ISG valuable we’re growth and high already synergies drive fact in I I alignment, way the years, or the opportunities revenue seeing, a think has some end-to-end in sent some with asset their very work them saw for as us together. fact And

well So Europe us lot consulting service side. in as footprint strength Jason? in the more on a Asia-Pac horsepower it the a gives bigger as in

Jason Meggs

Yes.

accretion, I the EPS this other period still short accretion in accretive it to is we given we’re there, what a more seeing items CapEx is although just see coming from year, being depreciation some think on slightly inferior lower year. just as and and The On the that’s Bob.

Operator

comes question from of John next our William Blair. Kreger And

Your now line is open.

John Kreger

Clinical the you seeing there? Commercial portfolio? give revenue Alistair, referred the in you’re guys unfavorable specifically Solutions. X is Can and an us I think what to just of And both update on back on Slide mix deck, the what you in unfavorable

Jason Meggs

John, here. it’s Jason

of timing into In through I little revenue. just a of both see little modifications that in certain contract fluctuations we the in in coming we we in driven that to one, of the look So in the did quarter-to-quarter call, items catching businesses mix the unfavorable as the a both see businesses, we both bit by, due then to XQ need see on year Commercial that instead bit predominantly of and something same businesses. up over side. the out It’s mentioned

John Kreger

Okay.

think should certain adjustments So kind and to that as margins? when we might hear that, of modifications have opposed types lower we businesses of

Jason Meggs

yes, instance, this can John. the it be former. instance, this it’s But both, yes, in In

John Kreger

one then, And you. for Jason, another

that at think, in just what some million benefits just your $X I line, seeing on things get kind was? EBITDA Can accelerated talked in expected to remarks, a the fourth that about elaborate you you quarter. you benefit -- and of the was

Jason Meggs

Yes.

bonuses continuing we et some to those last better of that things talked about line reversals we we’re come some some as just a of saw came end closing quarter of end review saw XQ. into out, that through KPI-based So the cetera. PTO and forward sight, year, that accrual of benefit could come fact come those and together of the through get integrate that the and And the We year. at the at the

that, sure already expected was year was additive an in to So it that guidance. I make the to and that clear we wanted had full just what

John Kreger

one. have versus you then Can floating remind And you one us the debt debt rate total how last much outstanding?

Jason Meggs

September XX% variable. fixed So as of about rate is of and we have end the XX%

Operator

And comes the Jefferies. of Windley David next question from

David Windley

then the think about off dedicating should prompted you handed that? Alistair, How as push efforts operational you’re segment. of in And has marketing primarily the resources element around you’re the whether of the my business to coordination it that is or talking and ISG kind of customer-facing to it been a and won continuing business. as I in ISG operational about question to kind mind to ISG,

Alistair MacDonald

of bit a it’s Dave, actually. Well, both,

of bandwidth middle evidence in a and now about and both So kind well, and the will Commercial out play the ISG and of that to all folks Clinical -- have connections the team business is dozen in pull their of there’s that our together. to by understanding Consulting who led

to of at role deliver look together. they across fits different prepare the then and we a They So the across able pulling role, coordination how continuum, all those proposition let the they’re a different way and in lead So right? way the customer all I’ll accelerate value and but the is that a organizations are. then coordination orientation Clinical kind work delivered the work Commercial a add, across lead in first and push. The of they same. the Michelle the different with It’s as

So the you that perspective. all I from the Michelle, think, view from Clinical Commercial --

Michelle Keefe

Sure.

So these Commercial, ISG across integration Clinical quickly our involved. they identifies commercial when the team get opportunities and

So we and that possible the umbrella that for the the have asset. team those have drive assets integrate to all to particular expertise we launch that a has best assets Commercial under really understanding how in of

And Clinical business. your Commercial and point, closely if occur into Commercial delivering does the so to if when very the But it’s we work unit Clinical David, day-to-day business the we get a the them. with unit in that work, of it’s operations

Alistair MacDonald

add also, coordination sales pitch. Dave. Yes. a one so not a as it’s different of of kind operational different I There’s delivery. It’s just will thing well, a lot

the same more order the expedited, more or a vigorous manner. in in more We’re less but same doing things

needed, Process sales. "In process it lining And think is to continue what hit us of the the them to compressing kind all what up, and we’re peak with they development." the this space seeing in from it say, on helps terms is market -- going time almost is it style, from what I the of we’re to feedback it’s when pace This need. and this get and drive of we’re the considerable this customer to to be saves to how So -- the Trusted going negotiating in is that dead the that customers expect the is

about, then speed. what that’s that So driving right, it’s all

David Windley

in much or to past, number? Is there wins. the maybe as over little update an $XXX I $XXX you’ve, as that a million of think, quantified And million

Alistair MacDonald

not this No, at time.

the award play a pulling Phase usual data effort general from strong big X you over QX, in like. that collaborative building We some I a had us ISG data, award had the think clinical a if team that group, was some very digital helped quarter medicine we win that ISG. between cysts competitors, suspect and real our

So typical consider but we’re with win we that it ISG contribution, what their more a clinical. wasn’t was pleased pretty would because

that we people hurdles of their hold And think do but want contingent off an as through evolves it want clinical. the don’t clinical I But wanted into little gets see it until that that facing more. they’re a what some of through company kind to to sometimes is ISG conversation still bit award are do interested, through to they’re they get because they to yet going of it, Clinical. they

David Windley

forwards about Okay. one one last you quarter, quickly. thinking real third. Jason, then And pull sounds fourth some -- had into EBITDA,

sequential impact all. fourth third with of net effect at at kind identified the kind the from the pointed some missed You’ve help me quarter to EBITDA? you of talked it think things about that EBITDA of kick in or I if quarter I in, fourth you’ve quarter. on you Can revenue. kind

Jason Meggs

with the we with through in in prepared growth of double-digit then of as the what and us revenue have So some and XQ coming that in for confident there. growth. on of see then the with can XXX the side, Dave, actual we we that feel QX terms four this we growth saw just talk side quarter guidance normal given XXX, line the we what XXX we’re back activity, and mix And to well. solving the did sequential sequential

Operator

Coldwell from comes question next with our Baird. And Eric

open. now is line Your

Eric Coldwell

rates once slower acceleration year. this toggling at everybody made something in versus implying I’m about gave FX possibly the commentary, more over a growth, for and and you XXX% what above was about When least quite really clear you qualitative that of clinical in versus growth I incremental rapid think XXXX, calls a clinical seeing year? kind more about what I’m little frankly, were we’ve talking be could starts, Revenue expectations? Commercial, when you commercial sorry, one I heard next acceleration some few specific talking hoping you with -- First just from you I’m you XXXX bit rates, morning. you’re headwinds; on were market. and comments on the the are that. just last on street not

Alistair MacDonald

start Yes. you to over Jason. pass I’ll and I’ll

Yes, think I we healthy on I Okay? mean, both see markets a sides.

number And looking we talked think back clinical, the over from from in on we just and accelerating conversations are of amount bit. do in add of our growth round bit in of little kind get little also customers, if they increasing you we’ve the already going momentum-wise of stride, a that terms in could also processes side, not in here As where develop, to the continues about of I sector. That Europe, environment the products at. it And the U.S. the into commercial more. outsourcing of Jason at approval intent we’re but like, with the the a then through

closely obviously that like, in you So track we that’s something very sector is in if our itself. because commercial actually major pharma competitor,

outsourcing But piece penetration So very that for is growth in on and that forecasting we important sentiment sector. when any... the is Jason, at look

Jason Meggs

yes. Yes,

if we at in look grew ‘XX. X.X% So clinical, you the growth,

the a to X% market in this There, going be always couple We’ve year. start-up range. in the We’re range we’ve looked that got X% that FX headwinds and with approximate the delays. at

year, sort easier the And X%. we acceleration last sort look year, launch were see off point. rate, digits from you contracted low of single an when commercial at this we However, growing of

above see and business. potentially on the getting that we coming that we we what healthy, X% of on being up that call growth market see, we see growth out backlog there pipeline the what the With

acceleration year-to-year So both we’re that’s businesses. what at, we’re looking seeing that the in

Alistair MacDonald

Yes.

Eric Coldwell

what see blueprint of having your advertisements. or looks in start talking to early this these are you Trump that in prices and obviously, pharmas about if recently then kind influence, pricing administration in That’s here how too drug have forcing that to changes I about just super positive some any transparency at terms think And of even Azar negative, the marketplace. what talked customers XXXX. are perhaps of a with maybe list they But the as on about coming business in to the helpful. And and their know. and technicality curious with Trump administration, I’m it’s direct-to-consumer

Alistair MacDonald

commentators, political us But to I’m I monitor thankfully, it. not comment to we market but that know we’re what’s sure Well, on allow not going right, obviously. on think. Yes. politicians

We’ve their well, in the constant about what in has We theater drug them. there discussions where impact with drug that threat pricing already. it’s European of pricing. customers We’re on as to seen operate approach growing

another got in from is what and helps yesterday front we’re with around customer that customer, and bring agencies NICE we to that the getting expecting that we other don’t like. where our tomorrow part drive a meeting do. need of agencies -- customers that into HEOR us of sit really Europe You’ve meeting business current almost kind they’re entail our day, knowledge a but to advantage see, what because to for that every got one And of packages those look

evidence then, clinical customers better pass point. to us design information gets And when enabling that commercial. across muster to that’s So they in into packages solutions, help obviously, to better going carried that get

about out this. is Michelle everyday talking and about So

want you to? do Michelle, So

Michelle Keefe

Yes.

things. of it’s So couple

we are And the talk that then political you that to in the things that team make treat time and patients them reacting to and pharma a you practice to would aware in and environment PR now, teams life of organizations constant relations and public are of variety designing to conversation pricing strategies would they in and a call on CEOs lot pharma how pharma a are they’re sciences. tracking with variety I what’s to working have this they right, it. think may And all at that Management, and their And may Reputation understand the spend may, are marketplace they’re C-Suite interpreting around C-Suite on going right disease of on around, how have. and the how states. We Risk this how impact medications think And have. with patients it’s really these I available our and about of trying

customers think I change to over to do with life we’re I I of our very science a think is time. we statement things happen. of positioned ready happens, our Because know all position have and believe I think don’t what situation strength, that. the we that that. well address going hand whatever on to we’re But we So to public think in we’re candidly, to make partner a pulse around

Eric Coldwell

I’m in past. one, quantify could I fantastic. Jason, the a if quickly. PTO reversals That’s last that. you surprise It’s know possibly you’ve accrual the curious talked My about about hear not total as on might your planning whether thoughts calendar change you’re you the And see for for on EBITDA impact or seeing of what ‘XX. adjusted XXXX any policies a result XXXX? in to

Jason Meggs

Yes.

front back we’ll to go So Eric. there,

continuing obviously, and rules GAAP within that looking are have So the and confines come as of, we harmonize there. that to U.S. at this we’ve together year been

out probably be say is in quarter Eric, quantify We don’t and we way the Last hand, will I we’re to as is it, that that that. you think but see have believe to going will -- hit year, sequential there restart did don’t quantified quarter have the that of margins. at this actually, year, you the X, come X, that not to about this what and --

So as into to we that’s quarter head that it, about we look think and probably way the could at X.

Operator

from And Draper SunTrust. the of next question comes Sandy

Sandy Draper

been of asked lot have A and answered. questions my

capital a just question. maybe So deployment

thoughts. Just get updated

You Or stock. commented Or more about in aggressive activity the cash Any more include more about you down you’ll debt? paying and are any to is down you back using it be paying tuck-in the on board how enough guidance targets? the end debt, up strong does there? repurchases. just on do focused thinking that leverage acquisitions think in level’s sort think tuck-in acquisitions, and buying When you repurchases, there priorities share willingness not update share of

Alistair MacDonald

Yes.

We we that then XXXX. wanted next opportunistic mean, the markets, Kinapse high-growing brought. at is remain We down, the So lot -- third along Xx across to like repurchase nimble leverage X, competitive want to synergies on a XXX probably knew priority like next getting revenue what We getting priority well share that and space. asset. being looking place And by and in priority then for end terms because the we commercial. remains of after clinical in go down of capabilities the to in those. And of opportunistic. the for they probably it does the space of us I us debt in M&A that approximately

do capability, to more And the we gaps more I to about more but work learn got more and in always model seeing that have as think the sectors. customers, and not and scale. maybe the both we where have we’re we we some we’ve listen

side. a interested tight, latent there’s etcetera, be couple So that around we’d the capability. constantly at of then where areas, And in in I adding the Asia market in we’re and Pac, is obviously, think, capability looking clinical in commercial

priorities: So anything pay and Jason, then those primary M&A the the X down debt, are share to... repurchase.

Operator

And ISI. the from next Ross comes question Evercore Muken of

Ross Muken

of window like versus be of on of confidence a sort in as and I’m going out new I trials the the And some control? just to mix, bookings So recruitment is just pushouts. given year, does your bigger think When and coming generally when into again versus is probably moving of of how drug up net just how the sort that the of continue to the maybe starting some in next your much back much is about kind to control maybe of trial mix you wins? are that general given that to what the time sequencing and this happened these burn getting complexity of studies? pharmas guess, are

Alistair MacDonald

Yes.

is actually. -- points, I you think the most it So hit of

start-up it’s complexity. So

approval amount actual to that that them, that of drug in to, and not locations just et a cetera, type picking are trials regulatory now lift it’s a some delivering you’ve are. gene -- therapy, obviously, factor. class the have Cell much but heavier the we’re heavier so we’re from a complexity these So up them that pathway of and much in the lift with got they pathways, or also taking a IRB, tremendous perspective, the

our a of a reprioritization another it it of It’s get of up -- and the slowing I out kind decision-making. get of an won’t with customers, but and and that control. running down to say of is way outside of elongation kind Some trial of one the

awarded. are trials So

trials moving more for the forward. They’re more complex. cetera. complex, We’re not just IP slowing whether are down the protocol’s start et them, point the seeing the almost that’s and cancellations, because is But awarded

the on on we’ve which revenue think for So is a capable on burn I trial. I that little said And seeing those brethren somebody guidance. gotten future account as areas, into that taking else it we’re of earlier a does that Because of think affect our that, call bit in type we’re more seen have that, of some and trend. the

what that I impacts XXXX? in but... we’ve mean, Jason, So in that we’ve how on us I how think we’ve -- factored reset, any in, further thoughts

Jason Meggs

FX headwind. Yes, I think mean, have we -- the yes. I the

where And looked on ultimately, We focused our is about. have that what at we’ve the are that we’re here we thought and fact book-to-bills delays expected. the

healthy. We’ve remains for there growth The got this EBITDA acceleration. pipeline EPS year. Our is the and

at So those are on. and that the things looking focused we’re

Operator

question next comes Tycho from Our of Peterson JPMorgan.

Tycho Peterson

a for have Jason. been at A lot of questions the this couple point, asked but

revenue Just driven EPS. the I curious talked -- to close? on quarter. in side, the clarify, that the adds intact fourth that But know think the here guidance on commercial, you to Kinapse really by fact deal was as is the about how kept just you much

Jason Meggs

Yes.

that And the drive business to commercial the looking and excluding to looking that, So the the in segment, said, into we’re in what business. year-on-year strategic we is capability we That that’s that returned obviously, to has the that were so adding rolling is guidance. that get. are Kinapse growth

So the the business Kinapse. is excluding of impacts still growing year-on-year,

Tycho Peterson

And one the then on EBITDA. guess, just XQ I clarification

the it the the why You components pull mix? XQ the million. out had But upside? get But the $X especially by does of beat? other be that parse by FX? guidance cut Can $X EBITDA question by million, you XQ Is if down the EBITDA earlier. revenue you maybe -- less forward I annual why XQ million, would $X with given go Is

Jason Meggs

that just It’s tightening bringing the down, and revenue range revenue related to Tycho. overall

up out the volume as tighten Just that and for being we see come the revenue. and prudent

Tycho Peterson

by $XXX cost about $XXX can then as implications million synergies. XXXX? increase? on should And directional margins on maybe million just the million of you $XX you upside then the about to Can target of that lastly, to just next think then how And we for talk just year, color? what longer-term EBITDA provide any that And us we drove think

Jason Meggs

Yes.

through it’s margins, start savings, across-the-board mute will the to we as going to done I seeing with there the business The color. sort the that growth the mix in be process, continue of labor, still could When just could board, to the and Alistair the really drive investments about year about that talked that. look some synergies growth. can the there across getting segment, earlier great procurement-driven thinking we’re I’ll but of make mean, exit So XXXX. and said, year the we any ahead facility, obviously, between Yes, we at job rate completed. of then in that next differences side, add need XXXX whether That a a we’re team’s incremental nonlabor run rationalization. And you on

can. million we’re taking So comment, of more that further look rate in ahead getting but we’re too we $XXX seeing do the let we continuing on ourselves. far not the but and at very And Alistair then XXXX, see to there? exit improve, focused still if I’ll

Alistair MacDonald

we as both mean, big efficiency. both are business, kind structure to at the for look commercial I optimized they of absolutely. delivery the Yes, the as the well constantly review of clinical, units, and business

potential both work $XXX still exiting and in day units, rate that for the talked XXXX. on But merger. about still the to million we’re of I the confident the $XXX we through in we X that run that going get opportunity We’re evaluate million on think to up

we’ve last thank review missing So to a the get through that consolidations that’s we’re structural job without customers. and HRIS for been with acceleration for and had beat dinner done, we night synergies. a efforts for And great challenges We’ve team had them ERP their that continuing the terrific that. to the consolidation, driving

world, lot office well-known kind consolidations more We’ve up and and bits keep a and of managing efficiently. in while all a of performance to on leases. they’re keep kind service around got of to take continue So out And with commerce. we’re the more get the roll really the that. but that Those got we’ve they time, pleased out to to

have cetera. So et into come XXXX, to that we

we’re confident at. where So yes, I’m pretty

from $XXX million. very we’re acceleration constantly sector. get in seeing we asking that I’m We’re that how million the $XXX for happy the And with the to

So...

Tycho Peterson

ask And if one here. quick I can follow-up in just Okay. closing

of to for Ross’ it Or burn, Just on levels to we these should expect insight do you have do kind any there? remain XQ? think you question, at the clinical backlog

Jason Meggs

It’s Yes. Jason.

as quarter did So the X in burn note. rate side, down on clinical you tick the

Some of a right, awards mathematically. XX, months, that the out is just tick of be, just that large to XX it rate’s quarter in X those might amount wherever had we down burning over fact things your going

the ‘XX, we at get winning. sort as we of that staying So a do higher quarters little back several normalize given to of to range, XX.X%. where that into more we that, looking bit the start see is up studies in not number, were a up where where types last to into we’re the guidance are, but But necessarily in back in in XX%, not it or the jumping that we

Operator

from comes question Erin Wright of next our Credit And Suisse.

Your is line open. now

Erin Wright

the Most that can you comment note? that? meaningful here. there would of any overall you of pricing environment, Have been on changes sort But questions my been have taken

Alistair MacDonald

No, not really.

I think been robust. the pretty pricing environment’s

service one we really. in any commercial FSP, across So I changes mean, is seen full that haven’t that

Erin Wright

in seeing the of across dynamics sort from be of customers you’re anything And payment working capital there count? I any anomalies then should or quarter? guess, you And investigators? there seeing times to can the shorter thinking Are you some or times longer discuss were payment we about latest

Jason Meggs

Jason. it’s Erin,

see large vocal that to pharma, debt. have when We reasonably of have to into terms. we move the been good news are further at you that often do is priced are financing to cost our further that arrangements continue and look extension there payment supply-chain they The quite going we as

will in where putting period we’re we and use. look capital So continue a delevering that to at to

together X. quarter have got terms mean, I in that quarter the businesses in the of we to ERP, corporate of the challenge nothing really speak a up continuing and both on quarter, on the that got little billing. In accounts. We had around where getting in behind bit the did together manage caught we X, to quarter we first clinical

So nothing really noteworthy in quarter X.

Operator

from And Barclays. of Meehan our next question comes Jack

open. now is line Your

Jack Meehan

quarter as we Kinapse that terms should help In think the mid-double-digit of just you leaping about the the quarter, get think how could remind the commercial off of step-up? with we just business? and in the from contribution starts parts us a moving contract fourth then as to us to in fourth the seasonality you XXXX, could point? just And normal And about in this the segment,

Alistair MacDonald

Yes.

the commercial from on mean from a you bookings the side. seasonality Jack, So perspective,

Jack Meehan

well. perspective I mean from a as revenue

little off side? in should think quarter the step-up is normally, a we terms of bit of commercial step-down on in -- that quarter? fourth how the the Just based about of first the a revenue phasing there Just a

Alistair MacDonald

Okay.

Jason Meggs

Yes.

sales fourth where and fourth solution quarter. So the KPIs step-up Jack, year commercial -- which have, bonuses, in the or some we finished etcetera, side, heavily tend your of business, sale you your the performance on more to KPIs see we the full do and a there the the via proportioned quarter get is to

ramp where see through, You pushed see their spend to your utilization things want customers cetera. budgets the to in et year, you’ll during get so a

down strong XQ So It’s as what’s you starting in the sort up the do clinical of XQ, on could And going solutions Because in commercial in see part be same was terms side? selling that businesses. in a on the could the, be quarter. tend to on little you the than pronounced first of XQ, side. as question teams and the you not on you depending so there Jack, just XQ it’s less see what a in what your pronounced of might

Jack Meehan

Yes.

the step-up, wins bridge Kinapse quarter that a quarter you’ve had new from versus to the that of Just of the much the full the fourth kind mid-double-digit for how going is quarter, third contribution acquisition?

Jason Meggs

Yes.

piece pull all the certainly, quarter not acquisition there. businesses. naturally seasonally it we months XQ what to some you through going. really some that a we is versus X call. some there X.X it’s to the the went driving of It selling is of through items terms so But just So see in revenue because months, is Kinapse we’re had material get that August, the then in did in in we X is in business also But And of driving so we solutions closed some starting X that. quarter of have in second seeing talked about quarter in it’s that -- see those wins I

Jack Meehan

a just Or sponsors more some a follow-up, to You’re the about There’s those I’d be side. be thoughts. have talked sales are large outsourcing? been customers. positive? as on contracts? curious with discussions And I’d any curious you view getting some Do your a as few Alistair, cost that your pharma going reduction around is of how get potential there concerns

Alistair MacDonald

I think on Yes, a you’re It’s spot concern. there.

watch to have it. You

pharma as them have in buy it. that You for variablized with whether a lower can cost looks be part to for costs, that we’re so option mean, of right careful sector, they to already regions you right we its a I up Anything? in or an that’s team positive. every existing areas, and running a and have that the day. in therapy But breathe the Michelle, live

Michelle Keefe

on costs And variablize sales the with around leaders So their conversations senior support. strategic each a partner more line. us about providing and talking having to companies in more pharma being and more more that we’re quarter, are wanting and

And payer seeing on base, blended with the the and more also geography saying, deployment to We’re really etcetera. on base, and the with a looking market at region going a specialist. or center for what call based what’s nurses have right reimbursement and desire sales strategy so reps customer that teams, the is

And are are backbone those purpose kinds that coming to flexibility, and and so of us to built have of we to operational more because kind customers teams. deploy more

point, for don’t deploying not line, channel we against we growth growth significant right see we but So do the people do in see see your the -- to in strategy brands. sales right the overall

well the going your not a point, sales positioned be -- is believe significant we’re to rep we growth scenario overall, So that the in future. where, to to in

Operator

And our of next UBS. question comes Brennan Daniel from

Daniel Brennan

you and understand know the clinical outlook. Jason, lower the quarter you did the the decline wanted But XQ also I to your have guys at bookings in referenced issues, led burn mix the you discussed to rate. time, strength study naturally of and revenue better I same a the this outlook. burn

just and can of you comment your wondering, burn levels, from I’m the you forward on current visibility So outlook provided? confidence in level

Jason Meggs

based obviously see at scrubbed talked came about. the we can through third backlog you -- coming the rigorously delays XQ, up in we’ve quarter that looked X on in and in Well, quarter in quite the what that we’ve

through to felt the attempted we saw metrics that make we we actually that and could to get we had production the everything So sure headcount come done. what when and visibility comfortable there work was do something the to

then did there’s X keep still the awards. down. backlog we And So it from quarter there the larger

about every we updated in So which like we’ve I what for doing looked it X can, of Dan, way the terms feel at guidance. on quarter we’re

Daniel Brennan

out growth X%. get will qualitative of are at just a number. And then teasing more on your I X%, implying asked be market bracket understand, X%, know commentary. to you in you X%, growing were clinical indicated that guys conversation, a on that commentary the if X% is the I XXXX clarity little But trying your I’m kind the by of clarify to bit so so outlook just above earlier the versus

Alistair MacDonald

seeing for we’re today. been. giving accelerating growth where not we’re we’ve But Well, guidance XXXX from

Confident X.X% ahead give We’ll not As today. Jason in We’ll X% in of QX. that did be we’re XXXX. the XXXX, accelerating be But that accelerating said, in year. guidance this we’ll ahead. all we giving

Jason Meggs

Yes. the we’re to looking keep and those The at point. in at, FX there, is this that delays are headwind thing mind Dan,

things and sort those of So just account. taking then market the think about into

Daniel Brennan

wouldn’t if couple earlier I believe mentioned the on the then a But you on remarks. in And your integrated I prepared asked win just offering, contract questions was there another you mind, call. know

integrated just versus you about bookings not quarter, the provide can details some this integrated. So

there? Just any color on you’re having success the

Alistair MacDonald

Phase into it won ISG with as of organization pulling mean, ISG how the the III them. helped which ISG and then actually a that that model. see III, that an us when we wait didn’t Phase assist med our a team. It’s III from go typically win takes I would we how on big big that a had get clinical just -- even book a it. in through they in together huge big gen that’s don’t over a drug commercialize though conversations we panning the group Phase team the it that assist bookings because as We When to award, wanted solution with ISG out, our hand Yes, pleased

ISG ISG. they’d do a award, booked we the we’re We’ve gone have So want booking. we very so to that, that say team taking the so ahead The in our if that’s award into a rules confident as us it, opportunities. nice straightaway, goes didn’t But clinical it if But you invested has with happy where market. pipeline grown. and it like, in that kind they that’s have clinical internal of and of and with regulations,

Operator

for closing concludes remarks. that conference turn I’d today. Alistair the MacDonald And for our like back to session over to question-and-answer

Alistair MacDonald

Thank you. Okay.

with solid happy very we’re quarter. the So

strong see for We and to differentiator good ISG commercial a us. clinical continued momentum, with providing

So, and for thank very continued your investment the you in much, your and everybody, attendance today, interest company.

So have a great day, you. Thank and good. be

Operator

you thank conference. does participating in gentlemen, for program. the and conclude today’s This Ladies

a day. have disconnect. all great may You Everyone,

Syneos Health (SYNH) 10 Nov 182018 Q3 Earnings call transcript